Rosenthal T, Kissin E, Jacob E T, Stern N, Levi Y, Adar R
Angiology. 1979 Feb;30(2):123-8. doi: 10.1177/000331977903000206.
SQ 20881, an angiotensin-converting enzyme inhibitor, was given to 12 patients with renovascular hypertension and to 1 patient with unilateral parenchymatous renal disease in order to evaluate the role of renin-angiotensin systems in their hypertension. Plasma renin activity (PRA) and aldosterone were assayed in systemic blood before and after the injection of SQ 20881. In 5 patients PRA was also measured separately in each renal vein. Blood pressure decreased, PRA increased, and aldosterone level decreased in the 12 renin-dependent patients. When PRA was sampled separately from each renal vein, the increase was larger on the side of the affected kidney. Four patients with a positive test underwent corrective surgery, and in all blood pressure became normal. SQ 20881 is a useful agent in evaluating the contribution of renin in patients with hypertension.
SQ 20881是一种血管紧张素转换酶抑制剂，为评估肾素-血管紧张素系统在12例肾血管性高血压患者和1例单侧实质性肾病患者高血压中的作用，将该药给予这些患者。在注射SQ 20881之前和之后测定全身血液中的血浆肾素活性（PRA）和醛固酮。在5例患者中还分别测量了每条肾静脉中的PRA。12例肾素依赖性患者的血压下降、PRA升高、醛固酮水平降低。当从每条肾静脉分别采集PRA时，患侧的升高幅度更大。4例试验阳性的患者接受了矫正手术，术后血压均恢复正常。SQ 20881是评估肾素在高血压患者中作用的一种有用药物。
